Molecular oncology of lung cancer

Shinichi Toyooka, Tetsuya Mitsudomi, Junichi Sou, Keiju Aokage, Masaomi Yamane, Takahiro Oto, Katsuyuki Kiura, Shinichiro Miyoshi

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Progress in genetic engineering has made it possible to elucidate the molecular biological abnormalities in lung cancer. Mutations in KRAS and P53 genes, loss of specific alleles, and DNA methylation of the tumor suppressor genes were the major abnormalities investigated between 1980 and the 2000s. In 2004, mutations in the epidermal growth factor receptor (EGFR) gene that cause oncogene addiction were discovered in non-small-cell lung cancers (NSCLCs), especially in adenocarcinomas. Because they are strongly associated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), a great deal of knowledge has been acquired in regard to both EGFR and other genes in the EGFR family and their downstream genes. Moreover, in 2007 the existence of the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene was discovered in NSCLC; and the same as EGFR-TKIs, ALK inhibitors are being found to be highly effective in lung cancers that have this translocation. These discoveries graphically illustrate that molecular biological findings are directly linked to the development of clinical oncology and to improving the survival rates of lung cancer patients. Here, we review the remarkable progress in molecular biological knowledge acquired thus far in regard to lung cancer, especially NSCLC, and the future possibilities.

Original languageEnglish
Pages (from-to)527-537
Number of pages11
JournalGeneral Thoracic and Cardiovascular Surgery
Volume59
Issue number8
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Lung Neoplasms
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
erbB-1 Genes
Mutation
Genetic Engineering
Medical Oncology
Gene Fusion
p53 Genes
DNA Methylation
Tumor Suppressor Genes
Oncogenes
Protein-Tyrosine Kinases
Adenocarcinoma
Survival Rate
Alleles
Genes
anaplastic lymphoma kinase

Keywords

  • Biology
  • Lung cancer
  • Molecular oncology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Molecular oncology of lung cancer. / Toyooka, Shinichi; Mitsudomi, Tetsuya; Sou, Junichi; Aokage, Keiju; Yamane, Masaomi; Oto, Takahiro; Kiura, Katsuyuki; Miyoshi, Shinichiro.

In: General Thoracic and Cardiovascular Surgery, Vol. 59, No. 8, 08.2011, p. 527-537.

Research output: Contribution to journalArticle

Toyooka, Shinichi ; Mitsudomi, Tetsuya ; Sou, Junichi ; Aokage, Keiju ; Yamane, Masaomi ; Oto, Takahiro ; Kiura, Katsuyuki ; Miyoshi, Shinichiro. / Molecular oncology of lung cancer. In: General Thoracic and Cardiovascular Surgery. 2011 ; Vol. 59, No. 8. pp. 527-537.
@article{0d3f59ec6ce34396aada13244d6e8681,
title = "Molecular oncology of lung cancer",
abstract = "Progress in genetic engineering has made it possible to elucidate the molecular biological abnormalities in lung cancer. Mutations in KRAS and P53 genes, loss of specific alleles, and DNA methylation of the tumor suppressor genes were the major abnormalities investigated between 1980 and the 2000s. In 2004, mutations in the epidermal growth factor receptor (EGFR) gene that cause oncogene addiction were discovered in non-small-cell lung cancers (NSCLCs), especially in adenocarcinomas. Because they are strongly associated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), a great deal of knowledge has been acquired in regard to both EGFR and other genes in the EGFR family and their downstream genes. Moreover, in 2007 the existence of the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene was discovered in NSCLC; and the same as EGFR-TKIs, ALK inhibitors are being found to be highly effective in lung cancers that have this translocation. These discoveries graphically illustrate that molecular biological findings are directly linked to the development of clinical oncology and to improving the survival rates of lung cancer patients. Here, we review the remarkable progress in molecular biological knowledge acquired thus far in regard to lung cancer, especially NSCLC, and the future possibilities.",
keywords = "Biology, Lung cancer, Molecular oncology",
author = "Shinichi Toyooka and Tetsuya Mitsudomi and Junichi Sou and Keiju Aokage and Masaomi Yamane and Takahiro Oto and Katsuyuki Kiura and Shinichiro Miyoshi",
year = "2011",
month = "8",
doi = "10.1007/s11748-010-0743-3",
language = "English",
volume = "59",
pages = "527--537",
journal = "General Thoracic and Cardiovascular Surgery",
issn = "1863-6705",
publisher = "Springer Japan",
number = "8",

}

TY - JOUR

T1 - Molecular oncology of lung cancer

AU - Toyooka, Shinichi

AU - Mitsudomi, Tetsuya

AU - Sou, Junichi

AU - Aokage, Keiju

AU - Yamane, Masaomi

AU - Oto, Takahiro

AU - Kiura, Katsuyuki

AU - Miyoshi, Shinichiro

PY - 2011/8

Y1 - 2011/8

N2 - Progress in genetic engineering has made it possible to elucidate the molecular biological abnormalities in lung cancer. Mutations in KRAS and P53 genes, loss of specific alleles, and DNA methylation of the tumor suppressor genes were the major abnormalities investigated between 1980 and the 2000s. In 2004, mutations in the epidermal growth factor receptor (EGFR) gene that cause oncogene addiction were discovered in non-small-cell lung cancers (NSCLCs), especially in adenocarcinomas. Because they are strongly associated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), a great deal of knowledge has been acquired in regard to both EGFR and other genes in the EGFR family and their downstream genes. Moreover, in 2007 the existence of the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene was discovered in NSCLC; and the same as EGFR-TKIs, ALK inhibitors are being found to be highly effective in lung cancers that have this translocation. These discoveries graphically illustrate that molecular biological findings are directly linked to the development of clinical oncology and to improving the survival rates of lung cancer patients. Here, we review the remarkable progress in molecular biological knowledge acquired thus far in regard to lung cancer, especially NSCLC, and the future possibilities.

AB - Progress in genetic engineering has made it possible to elucidate the molecular biological abnormalities in lung cancer. Mutations in KRAS and P53 genes, loss of specific alleles, and DNA methylation of the tumor suppressor genes were the major abnormalities investigated between 1980 and the 2000s. In 2004, mutations in the epidermal growth factor receptor (EGFR) gene that cause oncogene addiction were discovered in non-small-cell lung cancers (NSCLCs), especially in adenocarcinomas. Because they are strongly associated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), a great deal of knowledge has been acquired in regard to both EGFR and other genes in the EGFR family and their downstream genes. Moreover, in 2007 the existence of the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene was discovered in NSCLC; and the same as EGFR-TKIs, ALK inhibitors are being found to be highly effective in lung cancers that have this translocation. These discoveries graphically illustrate that molecular biological findings are directly linked to the development of clinical oncology and to improving the survival rates of lung cancer patients. Here, we review the remarkable progress in molecular biological knowledge acquired thus far in regard to lung cancer, especially NSCLC, and the future possibilities.

KW - Biology

KW - Lung cancer

KW - Molecular oncology

UR - http://www.scopus.com/inward/record.url?scp=80052769870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052769870&partnerID=8YFLogxK

U2 - 10.1007/s11748-010-0743-3

DO - 10.1007/s11748-010-0743-3

M3 - Article

C2 - 21850578

AN - SCOPUS:80052769870

VL - 59

SP - 527

EP - 537

JO - General Thoracic and Cardiovascular Surgery

JF - General Thoracic and Cardiovascular Surgery

SN - 1863-6705

IS - 8

ER -